Clinical Trial Update: A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing rhuFab V2 to Verteporfin photodynamic therapy for subfoveal neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Verteporfin photodynamic therapy (verteporfin)
• rhuFab V2 (rhuFab V2)

Snippet

Sponsor: Genentech, Inc. | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED